Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines

被引：7
作者：
Mitsiades, CS
Sykoutri, D
McMullan, C
Poulaki, V
Mitsiades, N
机构：
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Angiogenesis Lab, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | 2003年 / 88卷 / 10期
关键词：
D O I：
10.1210/jc.2003-030968
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：5043 / 5044
页数：2
相关论文
共 7 条
[1]   Bcr-Abl inhibition as a modality of CML therapeutics [J].
Buchdunger, E ;
Matter, A ;
Druker, BJ .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2001, 1551 (01) :M11-M18
[2]   Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J].
Druker, BJ ;
Tamura, S ;
Buchdunger, E ;
Ohno, S ;
Segal, GM ;
Fanning, S ;
Zimmermann, J ;
Lydon, NB .
NATURE MEDICINE, 1996, 2 (05) :561-566
[3]  
Druker BJ, 2002, J NATL CANCER I, V94, P1660
[4]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[5]   Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL(+) leukemic cells and induces apoptosis [J].
GambacortiPasserini, C ;
leCoutre, P ;
Mologni, L ;
Fanelli, M ;
Bertazzoli, C ;
Marchesi, E ;
DiNicola, M ;
Biondi, A ;
Corneo, GM ;
Belotti, D ;
Pogliani, E ;
Lydon, NB .
BLOOD CELLS MOLECULES AND DISEASES, 1997, 23 (19) :380-394
[6]   Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. [J].
Kantarjian, H ;
Sawyers, C ;
Hochhaus, A ;
Guilhot, F ;
Schiffer, C ;
Gambacorti-Passerini, C ;
Niederwieser, D ;
Resta, D ;
Capdeville, R ;
Zoellner, U ;
Talpaz, M ;
Druker, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) :645-652
[7]   The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells [J].
Podtcheko, A ;
Ohtsuru, A ;
Tsuda, S ;
Namba, H ;
Saenko, V ;
Nakashima, M ;
Mitsutake, N ;
Kanda, S ;
Kurebayashi, J ;
Yamashita, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (04) :1889-1896
1